St. Jude unveils Accent MRI pacemaker in India; BridgePoint, Covidien ink licensing deal;

> St. Jude Medical ($STJ) has launched the Accent MRI pacemaker and a Tendril MRI lead in India. The devices will allow patients to undergo full-body, high-resolution MRI scans. Report

> BridgePoint Medical is linking up with Covidien ($COV) in a deal that gives the device giant rights to peripheral vascular products, including the BigBoss and Mantaray catheters, as well as the Mantaray guidewire. Covidien also will obtain certain manufacturing assets from BridgePoint. Further terms of the agreement were not disclosed. BridgePoint release

> Bioject Medical Technologies has retained Snehal Patel to assist the company as it explores strategic alternatives, including a possible sale. Bioject release

> Recently presented data suggest that GE Healthcare's ($GE) [18F]Flutemetamol could add value to current diagnostic tools used to evaluate neurodegenerative conditions like Alzheimer's disease. The PET imaging agent is in Phase III development for the detection of beta amyloid. GE release

> Neuroscientists at Cold Spring Harbor Laboratory are developing a way to make highly detailed anatomical images of whole brains. Report

> Miraculins has filed a class II medical device license application with Health Canada for the PreVu noninvasive skin cholesterol point of care test. Miraculins release

And Finally... Ergonomic seats can be found in many places ... including the wheelchair. Engineers at the Institute for Energy and Mobility of the Berne University of Applied Science in Switzerland and R Going, a rehabilitation company, have developed an ergonomic seat for electric wheelchairs. Story

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.